Today: 1 May 2026
Salesforce (CRM) stock: Goldman starts with a Buy, Barclays lifts target — what to watch before Tuesday
13 January 2026
2 mins read

Salesforce (CRM) stock: Goldman starts with a Buy, Barclays lifts target — what to watch before Tuesday

New York, January 12, 2026, 20:14 EST — The market has closed.

  • Goldman Sachs kicked off coverage on Salesforce, assigning a Buy rating and setting a $330 price target; Barclays responded by raising its target to $338.
  • Shares closed Monday roughly 0.2% lower, at $259.40.
  • Tuesday’s U.S. CPI report and Salesforce’s conference comments are drawing investor attention for new clues on AI demand.

Salesforce, Inc. (CRM) shares dipped about 0.2% Monday, even as Goldman Sachs kicked off coverage with a Buy rating and a $330 price target. The stock wrapped at $259.40, after fluctuating between $255.81 and $261.55 during the session. Goldman’s price target implies roughly 27% upside from that close.

The call comes amid Wall Street’s scramble to figure out which software stocks will translate AI capabilities into actual paying customers in 2026. The mood remains upbeat: the S&P 500 ticked up 0.2%, closing at a new high on Monday.

Goldman analyst Gabriela Borges said AI adoption should act as a “positive tailwind” for software’s total addressable market and noted that Salesforce’s key metrics are “inflecting.” The bank projects Agentforce will boost Salesforce’s “Platform and Other” revenue by roughly 4% over the next 12 to 18 months, based on its analysis and company disclosures. StreetInsider.com

Barclays analyst Raimo Lenschow raised his price target to $338 from $330, maintaining an Overweight rating—indicating he expects the stock to outperform its peers. He pointed to a “favorable setup” for software in 2026, citing low valuations and steady IT spending. TipRanks

Barclays released a note Monday that triggered a wider reshuffle in the software sector. The firm upgraded Descartes Systems but downgraded Snowflake, DoubleVerify, and GitLab, according to .

Salesforce’s immediate challenge isn’t expanding its product lineup but convincing customers to shell out for AI and automation in the front office. That strategy puts it head-to-head with Microsoft’s business apps and emerging workflow players like ServiceNow, all facing the same pressure from buyers demanding clear ROI.

Salesforce is trading at $259.40, roughly 29% off its 52-week peak of $367.09. Its price has swung between $221.96 and $367.09 over the past year.

The company’s most recent major update came Dec. 3 with its third-quarter results, when it raised its fiscal 2026 revenue forecast to between $41.45 billion and $41.55 billion. CEO Marc Benioff announced: “We are raising fiscal year 2026 revenue guidance,” highlighting strong momentum from Agentforce and Data 360, which have driven nearly $1.4 billion in annual recurring revenue—a key subscription-sales figure. Salesforce Investor Relations

Salesforce will take the stage at the J.P. Morgan Healthcare Conference on Tuesday. Mark Sullivan, the company’s president of sales, is slated to speak at 2:15 p.m. Pacific time.

The macro test arrives earlier Tuesday. The December U.S. Consumer Price Index is set for release at 8:30 a.m. ET, a report that often shakes Treasury yields and rattles high-multiple software shares.

Salesforce is making a stop in Boston on Wednesday afternoon as part of its Agentforce World Tour. The company plans to hold sessions and roll out product updates, which will be available later via on-demand streaming, it said.

That bullish case hinges on smooth execution. Should customers delay adopting Agentforce or resist the pricing, the growth lift baked into the new targets might evaporate fast — and software multiples tend to shrink swiftly once the market grows wary.

Salesforce hasn’t confirmed when it’ll report earnings next. Nasdaq’s calendar shows Feb. 25 as the expected date. In the meantime, traders are focused on Tuesday’s CPI data and any Agentforce updates from conferences for fresh signals.

Stock Market Today

  • Investors Eye FTSE 250's Applied Nutrition as Diageo Shares Falter
    May 1, 2026, 11:39 AM EDT. Diageo shares have slumped about 30% over the past year and more than 50% in five years, pressuring investors. Applied Nutrition, a FTSE 250 nutritional supplement supplier, offers a contrasting growth story with a 57% rise in sales over six months and a near 90% rise in share price over one year. The company benefits from booming health and wellness trends, expects 8% market growth annually through 2028, and features strong financials including a £25.4 million net cash position, 49% return on capital, and a modest forward price-to-earnings ratio of 17.5. Its business-to-business model with retailers like Tesco and Amazon helps navigate industry competition. Investors seeking to recover losses from Diageo may consider Applied Nutrition's robust outlook and expanding market.

Latest article

Tempus AI’s Big May: Why Q1 Results and First Investor Day Put TEM Stock in Focus

Tempus AI’s Big May: Why Q1 Results and First Investor Day Put TEM Stock in Focus

1 May 2026
Tempus AI will report first-quarter results on May 5 and hold its first investor day on May 29. Merck’s CEO highlighted Tempus in remarks on the drugmaker’s AI efforts in precision oncology. Tempus shares traded near $55.44 Friday, with a market value of about $9.7 billion. The company reported 2025 revenue of $1.27 billion and forecast $1.59 billion for 2026.
Ciena Corporation Stock Faces $416 Reality Check as AI Network Push Heads to Brazil

Ciena Corporation Stock Faces $416 Reality Check as AI Network Push Heads to Brazil

1 May 2026
Rothschild & Co Redburn initiated Ciena with a Neutral rating and a $416 target, about 22% below Friday’s $534.43 share price, citing that much of the optical-networking upside is already priced in. Ciena reported Q1 revenue of $1.43 billion, up 33%, and raised its 2026 forecast. The company will showcase new optical products at ABRINT 2026 in São Paulo next week.
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land
Previous Story

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

Singapore Airlines stock slips as oil climbs on Iran fears; Feb 24 update looms
Next Story

Singapore Airlines stock slips as oil climbs on Iran fears; Feb 24 update looms

Go toTop